NCT03051100

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Triplet Therapy With Bempedoic Acid (ETC 1002) 180 mg, Ezetimibe 10 mg, and Atorvastatin 20 mg in Patients With Elevated LDL C

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 63 (actual)
• Sponsor: Esperion Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if triplet therapy with bempedoic acid (ETC-1002) 180mg, ezetimibe 10mg, and atorvastatin 20mg is effective and safe versus placebo in patients with elevated LDL cholesterol.

Conditions

• Hypercholesterolemia

Interventions

Type	Name	Description
DRUG	Bempedoic acid 180mg	bempedoic acid 180 mg
DRUG	Ezetimibe 10mg	ezetimibe 10 mg
DRUG	Atorvastatin 20mg	atorvastatin 20 mg
OTHER	Placebo	placebo

Timeline

• Start date: 2017-01-19
• Primary completion: 2017-06-01
• Completion: 2017-07-05
• First posted: 2017-02-13
• Last updated: 2020-04-03
• Results posted: 2020-04-03

Locations

11 sites across 1 country: United States

Regulatory

• FDA-regulated drug study